RBC
AZN icon

Ronald Blue & Co’s AstraZeneca AZN Stock Holding History

Ronald Blue & Co’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-13,655
Closed -$869K – 197
2015
Q3 		$869K Buy
13,655
+1,878
+16% +$124K 0.05% 86
2015
Q2 		$751K Buy
11,777
+2,695
+30% +$185K 0.04% 113
2015
Q1 		$622K Buy
9,082
+1,093
+14% +$75.9K 0.03% 140
2014
Q4 		$562K Sell
7,989
-3,057
-28% -$219K 0.03% 146
2014
Q3 		$789K Buy
11,046
+2,161
+24% +$158K 0.05% 101
2014
Q2 		$660K Sell
8,885
-12,429
-58% -$899K 0.04% 136
2014
Q1 		$1.38M Sell
21,314
-2,011
-9% -$130K 0.1% 55
2013
Q4 		$1.39M Buy
23,325
+1,857
+9% +$101K 0.1% 59
2013
Q3 		$1.11M Buy
21,468
+764
+4% +$38.4K 0.09% 62
2013
Q2 		$979K Buy
+20,704
New +$1.05M 0.08% 43

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
CI
Cambiar Investors Denver, Colorado $2.3B AUM 24.77% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
SCCM
Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

Ronald Blue & Co's AZN Position: Q4 2015 in Review

Ronald Blue & Co sold out of AstraZeneca (AZN) in Q4 2015, closing a stake of 13,655 shares — an estimated $869K sold.

Ronald Blue & Co first reported a position in AZN in Q2 2013 and held it in 10 quarters. The position peaked at $1.39M in Q4 2013. 390 funds tracked by Wall St. Rank hold AZN as of Q4 2015.

  • Ronald Blue & Co reported no remaining AstraZeneca position as of Q4 2015 after selling out during the quarter.
  • Ronald Blue & Co sold 13,655 AstraZeneca shares in Q4 2015, an estimated $869K.
  • Ronald Blue & Co first reported a position in AstraZeneca in Q2 2013 and held it in 10 quarters.
  • Ronald Blue & Co's AstraZeneca position peaked at $1.39M in Q4 2013.
  • 390 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2015.

Based on Ronald Blue & Co's 13F filing for Q4 2015, filed 11 Feb 2016.